Alzheimer’s Drug Benefits Called ‘Trivial’ in Major Review, Prompting Debate
Updated
Updated · Ars Technica · Apr 15
Alzheimer’s Drug Benefits Called ‘Trivial’ in Major Review, Prompting Debate
25 articles · Updated · Ars Technica · Apr 15
A major review has found that anti-amyloid Alzheimer’s drugs make no meaningful difference to patients’ cognition or dementia severity after 18 months.
The review, analysing 17 studies with over 20,000 patients, also highlighted increased risks of brain swelling and bleeding associated with these treatments.
Charities and some researchers argue the review unfairly combines failed and newer drugs, cautioning against dismissing modest benefits for early-stage patients.
Are new Alzheimer's drugs worth the risk of brain bleeds for a small delay in decline?
Following multiple patient deaths, are the new FDA safety warnings for Leqembi strong enough?
With costs in the tens of thousands, can health systems ever afford these new Alzheimer's drugs?
Will at-home injections make controversial Alzheimer's treatments a new reality for millions?
Did a landmark review just kill the leading theory of Alzheimer's disease?
If not amyloid, what is the next breakthrough target for Alzheimer's drug research?